Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip (2023). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. , 25(1), DOI: https://doi.org/10.1016/s1470-2045(23)00529-6.
Article153 days agoPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Tim Akhurst, Ramin Alipour, Arun Azad, Patricia Banks, Alexis Beaulieu, James Buteau, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew D. Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. , 23(11), DOI: https://doi.org/10.1016/s1470-2045(22)00605-2.
Article153 days agoStereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Sandhu, Ben Tran, Arun Azad, Jeremy Lewin, Katharine Cuff, Nitika Neha, Duncan Colyer, Paul J. Neeson, Howard Liu, Sarat Chander, Daniel Moon, Jeremy Goad, Declan G. Murphy, Nathan Lawrentschuk, David Pryor (2021). Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.. , 39(6_suppl), DOI: https://doi.org/10.1200/jco.2021.39.6_suppl.277.
Article153 days agoCirculating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of <sup>177</sup>Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).
Anis Hamid, Michael S. Hofman, Mathias Bressel, Louise Emmett, Anthony M. Joshua, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, Anupama Pasam, Jason Callahan, Alisa Tubbs, Luisa Fernandez, Richard Wenstrup, Grace Kong, Jeremy Lewin, Ben Tran, Arun Azad, Joseph D. Schonhoft, Rodney J. Hicks, Shahneen Sandhu (2022). Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of <sup>177</sup>Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.5027.
Article153 days agoPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Tim Akhurst, Ramin Alipour, Arun Azad, Patricia Banks, Alexis Beaulieu, James Buteau, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew D. Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. , 23(11), DOI: https://doi.org/10.1016/s1470-2045(22)00605-2.
Article153 days ago